Strategies to Allow Family Visits to Acute Care Units During the Covid-19 Pandemic

Rana, MA; ARIF, B; SIDDIQUI, MH; Raza, Sania S.; Hashmi, M S; Hafeez, MM

doi:10.54112/pjicm.v2021i1.7

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 When an employee finds themselves in a strange new situation, he or she experiences anxiety that may prevent them from learning how to do their jobs. 19 A good orientation helps reduce the anxiety that results from entering an unfamiliar situation and helps provide guidelines for behaviour and conduct, so the employee doesn't have to experience the stress of guessing. 20 All new redeployed doctors should attend and complete the orientation program.…”

Section: Discussionmentioning

confidence: 99%

Experiences of Non-ICU Physicians Redeployment in ICU during COVID-19

Mady¹,

Odat²,

Ramadan³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Background: During the COVID-19 pandemic, enormous pressure on health care services resulted in a significant shift of work force from different departments of the hospital to the intensive care unit. Objective: To study the impact of redeployment on doctors and to focus on the factors affecting their satisfaction levels. Study Design: Cross-sectional study Place and Duration of Study: Riyadh First Health from 1st April 2021 to 30th September 2021. Methods: Sixty-six respondents were included. Results: Most physicians (59.1%) had no choice before being redeployed to the ICU. The proportion of happy and very happy doctors was 45.5%. A total of seven participants felt very unhappy when they were deployed to the ICU, six of them had no choice and only one had the option to redeploy. Prior to redeploy to the ICU, 37 (56.1%) doctors received orientation, among them 54.05% found it useful. Thirteen participants indicated that they were unclear about their role and 8 (61.5%) of them did not attend the orientation course. 68.2% of doctors worked more than 36 hours a week and 63.6% complained that the number of hours was greater than that of the previous department. 69.7% of doctors found their deployment useful for patient care, while 22.7% were neutral. 62.1 % doctors felt the deployment was beneficial for them and 59.1% felt satisfaction in fulfilling their role and 27.3% were neutral. Forty two (50%) were satisfied with their ICU redeployment and 33.3 % was neutral. Conclusion: By opting few measures, satisfaction levels of redeployed doctors can be boosted. This includes adequate administrative support, a well-organized orientation that clarifies the role of physicians and helps to elevate their morale. Before redeployment physicians should be given a choice so that they can freely join the ICU.

show abstract

Section: Discussionmentioning

confidence: 99%

Experiences of Non-ICU Physicians Redeployment in ICU during COVID-19

Mady¹,

Odat²,

Ramadan³

et al. 2022

PJMHS

View full text Add to dashboard Cite

show abstract

“…14 Between the ages of 40 and 50, the creation of new naive T-cells decreases rapidly, reducing the elderly's ability to combat emerging viruses like SARS-CoV-2. Diabetes and hypertension are two instances of comorbidities that are becoming more frequent as individuals age 15,16 .…”

Section: Discussionmentioning

confidence: 99%

Assessment of Predictors of Mortality in COVID-19 Patients Treated with Tocilizumab

Rana¹,

Qayyum²,

Siddiqui³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Background: A hypersensitivity condition called cytokine storm is the main cause of death in COVID-19 patients. A monoclonal antibody called tocilizumab may be able to suppress the Interleukin-6 receptors (IL-6R) and lessen the likelihood that the body would have a hypersensitive immune response. Aim: To evaluate the mortality advantages of tocilizumab in individuals with COVID-19. Study design: Retrospective study. Place and duration of study: Bahria Town International Hospital Lahore from 16th June 2020 to 17th September 2021. Methodology: Patients with 96 confirmed instances of COVID-19 were enrolled. Two groups of patients were created. A single dosage of tocilizumab was administered to 52 participants in the first group, referred to as the survivors, and 44 patients in the second group, who passed away within 14 days. From the patients' medical records, the demographic information, co-morbid conditions, and laboratory values were obtained. The hospital's institutional review board and ethics committee (IRBEC) gave its approval for this study. The permission was ignored because this was a retroactive analysis. Results: 54.24 16.58 was the average age, and 54 (56.25%) of the population were men. 52 (54.16%) patients were survivors, compared to 44(45.83%) patients in the non-survivor group. In non-survivors compared to survivors, the older age group was shown to be statistically significant (62.78±12.86 vs. 51.65±11.68, p=0.003). Additionally, non-survivors had a greater BMI (p=0.006). In our study, hypertension and diabetes were the two co-morbid conditions that were most frequently detected (35.24% and 28.94%, respectively). The mortality rates among patients with diabetes, asthma, COPD, and cancer were all considerably higher (P=0.01, 0.006, and 0.004, respectively). Cancer and type-2 diabetes patients had death rates that were considerably higher (p=0.05 and p=0.01, respectively). C-reactive protein (CRP), D. Dimer, procalcitonin (PCT), and IL-6 were discovered to be the significant predictors of mortality (p 0.0001, 0.05, 0.001, and 0.004 respectively). Conclusion: Even though tocilizumab is authorised and has been shown to have positive results, people with diabetes, COPD, and asthma are more likely to experience negative results even after getting a single dosage of the medication. Similar to CRP, D. Dimer levels are reliable indicators of death. Keywords: Tocilizumab, Motility predictors, Co-morbid conditions, COVD-19, Procalcitonin, D. Dimer

show abstract

Strategies to Allow Family Visits to Acute Care Units During the Covid-19 Pandemic

Cited by 2 publications

References 25 publications

Experiences of Non-ICU Physicians Redeployment in ICU during COVID-19

Experiences of Non-ICU Physicians Redeployment in ICU during COVID-19

Assessment of Predictors of Mortality in COVID-19 Patients Treated with Tocilizumab

Contact Info

Product

Resources

About